Published in J Virol on September 01, 2004
Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol (2007) 2.71
Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine (2009) 1.14
Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins. Vaccine (2007) 0.92
Adjuvanted influenza vaccine administered intradermally elicits robust long-term immune responses that confer protection from lethal challenge. PLoS One (2010) 0.91
Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways. J Virol (2010) 0.89
Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes. Expert Opin Biol Ther (2010) 0.84
Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults. Hum Vaccin Immunother (2013) 0.82
Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell (2015) 0.78
Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease. Antiviral Res (2014) 0.78
Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease. Virology (2014) 0.77
Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus. Antiviral Res (2015) 0.76
Preparation of mucosal nanoparticles and polymer-based inactivated vaccine for Newcastle disease and H9N2 AI viruses. Vet World (2017) 0.75
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev (1983) 7.16
Hydrogen peroxide mediates amyloid beta protein toxicity. Cell (1994) 5.19
A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods (1988) 4.70
An enzyme-release assay for natural cytotoxicity. J Immunol Methods (1983) 3.36
HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med (1997) 3.22
Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol (2001) 3.05
Overview of the mucosal immune system. Curr Top Microbiol Immunol (1989) 2.64
Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol (2001) 1.84
Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine (2003) 1.78
Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses. J Exp Med (1995) 1.78
Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest (2001) 1.63
Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J Immunol (2001) 1.54
Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine (1992) 1.49
Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein. J Virol (2000) 1.48
Induction of CD4(+) T-cell-independent immunoglobulin responses by inactivated influenza virus. J Virol (2000) 1.44
Hemagglutination-inhibition: rapid assay for neuraminic acid-containing viruses. J Virol (1974) 1.42
Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J Infect Dis (1999) 1.41
Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immunol (1992) 1.40
Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol (1992) 1.38
Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J Virol (2002) 1.36
Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system. J Virol (2003) 1.23
Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine (2000) 1.22
DNA vaccines, combining form of antigen and method of delivery to raise a spectrum of IFN-gamma and IL-4-producing CD4+ and CD8+ T cells. J Immunol (2003) 1.17
Evaluation of live and inactivated influenza A virus vaccines in a mouse model. J Infect Dis (1982) 1.10
High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160. AIDS Res Hum Retroviruses (1997) 1.10
Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. Virology (2003) 1.07
Secretion of a truncated form of the human immunodeficiency virus type 1 envelope glycoprotein. Virology (1993) 1.05
Production and characterization of simian--human immunodeficiency virus-like particles. AIDS Res Hum Retroviruses (2000) 1.04
Immunostimulatory DNA is a potent mucosal adjuvant. Cell Immunol (1998) 1.00
Identification of multiple simian immunodeficiency virus (SIV)-specific CTL epitopes in sooty mangabeys with natural and experimentally acquired SIV infection. J Immunol (2000) 1.00
CpG DNA as mucosal adjuvant. Vaccine (1999) 0.96
A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes. AIDS Res Hum Retroviruses (1998) 0.93
Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus. J Virol (2003) 0.92
Identification of SIV env-specific CTL in the jejunal mucosa in vaginally exposed, seronegative rhesus macaques (Macaca mulatta). J Med Primatol (2000) 0.90
Influenza virus-stimulated generation of anti-human immunodeficiency virus (HIV) activity after influenza vaccination in HIV-infected individuals and healthy control subjects. J Infect Dis (2001) 0.89
Comparison of in vitro immunostimulatory potential of live and inactivated influenza viruses. Hum Immunol (2000) 0.89
Efficient purification and rigorous characterisation of a recombinant gp120 for HIV vaccine studies. Vaccine (1995) 0.87
Induction of immune responses to SIV antigens by mucosally administered vaccines. AIDS Res Hum Retroviruses (1999) 0.87
B cell superstimulatory influenza virus (H2-subtype) induces B cell proliferation by a PKC-activating, Ca(2+)-independent mechanism. J Immunol (1995) 0.86
Murine pneumotropic virus VP1 virus-like particles (VLPs) bind to several cell types independent of sialic acid residues and do not serologically cross react with murine polyomavirus VP1 VLPs. J Gen Virol (2003) 0.86
Carrier-mediated uptake and presentation of a major histocompatibility complex class I-restricted peptide. Eur J Immunol (1993) 0.85
Infection with influenza a virus leads to flu antigen-induced cutaneous anaphylaxis in mice. J Invest Dermatol (2002) 0.83
Purification and characterization of simian immunodeficiency virus (SIVmac) envelope glycoprotein gp130 from virus-infected cells. Vaccine (1994) 0.81
Costimulation by B7 modulates specificity of cytotoxic T lymphocytes: a missing link that explains some bystander T cell activation. J Exp Med (1997) 0.81
Induction of cytotoxic and helper T cell responses by modified simian immunodeficiency virus hypervariable epitope constructs. Viral Immunol (1999) 0.80
Influenza A virus hemagglutinin is a B cell-superstimulatory lectin. Med Microbiol Immunol (1996) 0.80
Baculovirus infection does not alter N-glycosylation in Spodoptera frugiperda cells. Biol Chem Hoppe Seyler (1994) 0.79
Neutralizing antibody induced in mice by novel glycoconjugates of human immunodeficiency virus type 1 gp120 and env2-3. J Infect Dis (2002) 0.77
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med (2011) 7.29
Programming the magnitude and persistence of antibody responses with innate immunity. Nature (2011) 5.18
Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol (2010) 4.34
Gain-of-function experiments on H7N9. Science (2013) 3.67
Dissolving polymer microneedle patches for influenza vaccination. Nat Med (2010) 3.24
Original antigenic sin responses to influenza viruses. J Immunol (2009) 2.76
Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol (2007) 2.71
Shear stress induces endothelial differentiation from a murine embryonic mesenchymal progenitor cell line. Arterioscler Thromb Vasc Biol (2005) 2.51
Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol (2009) 2.44
Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn (2009) 2.35
Avian flu: Gain-of-function experiments on H7N9. Nature (2013) 2.32
Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg (2009) 2.31
Pause on avian flu transmission research. Science (2012) 2.24
Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog (2012) 2.09
Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta (2009) 2.08
Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol (2007) 2.06
Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One (2009) 1.95
Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther (2008) 1.90
Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci U S A (2009) 1.82
Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression. Proc Natl Acad Sci U S A (2007) 1.81
Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS One (2009) 1.78
HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol (2002) 1.78
ZIP4 upregulates the expression of neuropilin-1, vascular endothelial growth factor, and matrix metalloproteases in pancreatic cancer cell lines and xenografts. Cancer Biol Ther (2010) 1.63
Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release (2009) 1.62
MicroRNA-196: critical roles and clinical applications in development and cancer. J Cell Mol Med (2011) 1.59
Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer (2006) 1.59
Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems. J Cell Mol Med (2009) 1.51
Influenza vaccines based on virus-like particles. Virus Res (2009) 1.48
Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res (2006) 1.45
Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus. PLoS One (2011) 1.44
Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One (2010) 1.44
Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res (2007) 1.43
Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer (2010) 1.43
Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS One (2009) 1.42
Influenza virus inhibits ENaC and lung fluid clearance. Am J Physiol Lung Cell Mol Physiol (2004) 1.40
Norwalk virus does not replicate in human macrophages or dendritic cells derived from the peripheral blood of susceptible humans. Virology (2010) 1.40
Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One (2011) 1.40
Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology (2010) 1.39
Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med Sci Monit (2005) 1.37
Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis (2010) 1.36
Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets (2011) 1.36
Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol (2008) 1.34
Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine (2006) 1.33
Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr (2007) 1.32
Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection. Vaccine (2006) 1.32
Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther (2012) 1.31
Down-regulation of ZIP4 by RNA interference inhibits pancreatic cancer growth and increases the survival of nude mice with pancreatic cancer xenografts. Clin Cancer Res (2009) 1.30
Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One (2010) 1.28
Development of small-diameter vascular grafts. World J Surg (2007) 1.27
Two domains that control prefusion stability and transport competence of the measles virus fusion protein. J Virol (2006) 1.26
Structural features of paramyxovirus F protein required for fusion initiation. Biochemistry (2003) 1.26
Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. J Virol (2007) 1.25
Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: an update. Med Sci Monit (2010) 1.24
A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine (2008) 1.24
Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis (2011) 1.24
Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology (2006) 1.23
Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors. Cancer (2004) 1.22
Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology (2008) 1.22
Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A (2010) 1.22
Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol (2010) 1.22
Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol (2012) 1.22
Inhibition of influenza infection by glutathione. Free Radic Biol Med (2003) 1.20
Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis (2011) 1.20
Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J Virol (2009) 1.20
Mutations in the putative HR-C region of the measles virus F2 glycoprotein modulate syncytium formation. J Virol (2003) 1.20
Ceramide: a common pathway for atherosclerosis? Atherosclerosis (2007) 1.19
Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. Mol Cancer Res (2008) 1.19
LKB1 mutation in large cell carcinoma of the lung. Lung Cancer (2006) 1.19
A target site for template-based design of measles virus entry inhibitors. Proc Natl Acad Sci U S A (2004) 1.18
Human immunodeficiency virus protease inhibitor ritonavir inhibits cholesterol efflux from human macrophage-derived foam cells. Am J Pathol (2007) 1.17
Design of a small-molecule entry inhibitor with activity against primary measles virus strains. Antimicrob Agents Chemother (2005) 1.17
Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine (2009) 1.16
Palmitoylation of the murine leukemia virus envelope protein is critical for lipid raft association and surface expression. J Virol (2002) 1.16
Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Virology (2005) 1.16
Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J Immunother (2009) 1.16
Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression. Mol Cancer (2011) 1.16
Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology (2007) 1.16
Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease. J Surg Res (2005) 1.16
Current update on HIV-associated vascular disease and endothelial dysfunction. World J Surg (2007) 1.15
Expression and function of a large non-coding RNA gene XIST in human cancer. World J Surg (2011) 1.15
Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells. Blood (2008) 1.15
Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine (2009) 1.14
Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep (2012) 1.14
ZIP4 regulates pancreatic cancer cell growth by activating IL-6/STAT3 pathway through zinc finger transcription factor CREB. Clin Cancer Res (2010) 1.13
MicroRNAs: control and loss of control in human physiology and disease. World J Surg (2009) 1.12
Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets (2008) 1.11
Human stanniocalcin-1 blocks TNF-alpha-induced monolayer permeability in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol (2008) 1.09
Cyclophilin A: potential functions and therapeutic target for human cancer. Med Sci Monit (2009) 1.09
Nonpeptide inhibitors of measles virus entry. J Med Chem (2006) 1.08
IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-1 expression in pancreatic cancer cells. Cancer Biol Ther (2007) 1.08